BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today reported that the focus at the annual Society of Thermal Medicine (STM) conference, which was held in New Orleans from April 29 to May 2, 2011, was the increasing clinical use of hyperthermia in the treatment of cancer. The researchers at the meeting presented data showing significant benefits for the use of hyperthermia to treat a variety of tumors, including breast, prostate, head and neck, cervix, soft tissue sarcomas and bladder cancer. A number of presentations also discussed the importance of studying the use of hyperthermia and chemotherapy for the treatment of non-muscle invasive bladder cancer.
BSD and STM joined efforts to sponsor a BSD User Conference as part of the recent STM conference. Representatives from 27 clinical centers participated in the BSD User Conference to provide a springboard for increased clinical use of hyperthermia for the treatment of cancer.
During the STM meeting, Dr. Ruediger Wessalowski, University of Duesseldorf, Duesseldorf, Germany, presented clinical data showing the successful use of hyperthermia and chemotherapy, using the BSD-2000 Hyperthermia System, for the treatment of aggressive pediatric cancers, mainly germ cell and soft tissue sarcoma tumors. Dr. Wessalowski reported the striking results from treatment of 44 pediatric and adolescent patients; 25 of the 44 patients show no evidence of disease during a median follow-up period of 13 months (1-63 months) post-treatment. Dr. Wessalowski reported, "This prospective analysis of the Hyper-PEI project for children and adolescents with malignant diseases unequivocally demonstrated that additional RHT [Regional Hyperthermia] can dramatically improve the likelihood of the local tumor control by surgery, and can facilitate long-term remission and survival in the majority of patients in this prognostically very unfavorable patient group." The Duesseldorf pediatric oncology department pioneered the application of hyperthermia therapy using the BSD-2000 Hyperthermia System for the treatment of certain pediatric tumors.
The keynote lecture was presented by Dr. Rolf Issels, University Hospital Medical Center Klinikum Grosshadern, Munich, Germany. Dr. Issels was the primary investigator for a multi-center, Phase III, clinical study of hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy for the treatment of high-risk soft-tissue sarcoma cancer patients. Dr. Issels reported updated results from this study. Dr. Issels reported that hyperthermia in conjunction with chemotherapy offers a new standard treatment option for patients with high risk soft tissue sarcoma. The results demonstrated that the addition of hyperthermia to chemotherapy significantly improved tumor reduction, disease-free survival and time to disease progression for high risk soft tissue sarcoma patients.
Source:
Society of Thermal Medicine (STM)
BSD Medical Corporation
BSD and STM joined efforts to sponsor a BSD User Conference as part of the recent STM conference. Representatives from 27 clinical centers participated in the BSD User Conference to provide a springboard for increased clinical use of hyperthermia for the treatment of cancer.
During the STM meeting, Dr. Ruediger Wessalowski, University of Duesseldorf, Duesseldorf, Germany, presented clinical data showing the successful use of hyperthermia and chemotherapy, using the BSD-2000 Hyperthermia System, for the treatment of aggressive pediatric cancers, mainly germ cell and soft tissue sarcoma tumors. Dr. Wessalowski reported the striking results from treatment of 44 pediatric and adolescent patients; 25 of the 44 patients show no evidence of disease during a median follow-up period of 13 months (1-63 months) post-treatment. Dr. Wessalowski reported, "This prospective analysis of the Hyper-PEI project for children and adolescents with malignant diseases unequivocally demonstrated that additional RHT [Regional Hyperthermia] can dramatically improve the likelihood of the local tumor control by surgery, and can facilitate long-term remission and survival in the majority of patients in this prognostically very unfavorable patient group." The Duesseldorf pediatric oncology department pioneered the application of hyperthermia therapy using the BSD-2000 Hyperthermia System for the treatment of certain pediatric tumors.
The keynote lecture was presented by Dr. Rolf Issels, University Hospital Medical Center Klinikum Grosshadern, Munich, Germany. Dr. Issels was the primary investigator for a multi-center, Phase III, clinical study of hyperthermia, using the BSD-2000 Hyperthermia System, combined with chemotherapy for the treatment of high-risk soft-tissue sarcoma cancer patients. Dr. Issels reported updated results from this study. Dr. Issels reported that hyperthermia in conjunction with chemotherapy offers a new standard treatment option for patients with high risk soft tissue sarcoma. The results demonstrated that the addition of hyperthermia to chemotherapy significantly improved tumor reduction, disease-free survival and time to disease progression for high risk soft tissue sarcoma patients.
Source:
Society of Thermal Medicine (STM)
BSD Medical Corporation
Posts
0 comments:
Post a Comment